If polymorphs of the neutral chemical asset do not exist, do not provide the desired properties, or do not solve solubility, stability, crystallinity, handling, or manufacturability problems, an ionizable molecule may require pharmaceutical salt screening. Selection criteria should connect counterion strategy, crystallinity, solubility, stability, hygroscopicity, manufacturability, disproportionation risk, and analytical characterization to the molecule’s development stage and intended product.
Pharmaceutically acceptable counterions are selected using the API pKa, prior clinical and market use, toxicology, screening precedent, regulatory expectations, and intended route of administration. The goal is not merely to make a salt, but to identify a salt that can be crystallized, characterized, controlled, formulated, and justified.
Useful salt forms can improve crystallinity, solubility, dissolution, stability, and manufacturability. However, salt forms can also create hydrate/solvate, hygroscopicity, morphology, or disproportionation risks that must be evaluated before the selected form anchors tox, clinical, or product decisions.
| Salt-selection driver | What must be tested | Decision output |
|---|---|---|
| Ionizable API with poor solubility | Counterion set, pH-solubility, crystalline salt formation, slurry conversion, dissolution, and residual-solid analysis. | Salt candidates ranked by solubility, crystallinity, stability, and developability. |
| Stability or handling problem | Humidity stress, DVS, hydrate/solvate checks, thermal behavior, microscopy, XRPD/Raman/IR fingerprints. | Selected salt with stress behavior and open-risk statement. |
| Formulation pH or excipient risk | Disproportionation testing under water activity, pH microenvironment, and formulation-relevant excipients. | Formulation-control recommendation and monitoring method. |
A defensible salt-selection package should also state why rejected salts were rejected. Poor crystallinity, unstable hydration, rapid disproportionation, unacceptable hygroscopicity, poor isolation, problematic morphology, or weak analytical specificity can be more important than an early solubility advantage.
A salt can revert toward the neutral free acid or free base if local pH, water activity, excipients, or counterion environment favor the neutral form. The result can be lower apparent solubility, altered dissolution, instability, or crystallization of the free form.
This risk is highest when the salt is marginally stable, the formulation contains hygroscopic or pH-modifying excipients, or processing introduces water. For this reason, salt screening should be connected to drug-product conditions rather than evaluated only as neat API.
Disproportionation risk should be treated as a solid-form and formulation problem together. A neat API result can miss the local pH and water-activity effects created by excipients, granulation fluid, residual solvent, or packaging conditions.
Salt selection starts with ionization chemistry, but the selection decision is broader than pKa. The program has to choose a form that can be made reproducibly, characterized unambiguously, formulated safely, and controlled through humidity, solvent, excipient, processing, and storage conditions.
Triclinic connects counterion choice to developability: crystallinity, solubility, dissolution, hygroscopicity, hydrate or solvate risk, morphology, disproportionation, analytical specificity, and downstream manufacturing needs.
Use this decision tree to connect form selection, form control, formulation, process development, method development, release testing, stability, and lifecycle risk before the examples and publications section.
Salt selection can be an efficient exposure-rescue path for an ionizable API, but a salt should not be selected only because it forms quickly or dissolves faster in a first experiment. Counterion acceptability, delta pKa logic, route, drug loading, crystallinity, manufacturability, hygroscopicity, disproportionation, and polymorphism within the salt all affect developability.
The practical question is whether the salt can be isolated, dried, milled, formulated, stored, monitored, and reproduced without reverting toward the free acid or free base under product-relevant microenvironments.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Crystallinity | Poorly crystalline salts can be difficult to isolate, dry, mill, or release reproducibly. | Confirm by XRPD, microscopy, DSC/TGA, and lot reproducibility. |
| Hygroscopicity | Water uptake can drive deliquescence, hydrate formation, poor flow, or packaging burden. | Use DVS, controlled-RH stress, water-content testing, and post-stress form ID. |
| Disproportionation | Local pH, water activity, and excipients can push a salt toward the neutral form. | Test excipient compatibility, wet-process stress, dissolution, and residual solids. |
| Salt polymorphism | The chosen salt may have multiple forms with different properties. | Run a salt-specific polymorph screen and thermodynamic ranking. |
Salt and cocrystal classification can depend on proton position, ionization state, and crystal-structure evidence. The same API/coformer pair may sit near a salt-cocrystal continuum, making structural and spectroscopic interpretation important for regulatory and IP decisions.
Triclinic links XRPD, Raman/IR, ssNMR, thermal analysis, microscopy, solubility, and crystallization behavior to the practical question: is the selected form developable and controllable under the intended product conditions?
Determine whether an API can exist in multiple crystalline forms and whether form differences change solubility, dissolution, stability, manufacturing, drug-product performance, or IP.
View serviceUse coformer selection, phase-diagram logic, crystallization methods, and formulation strategy to improve properties and expand solid-form options.
View serviceCharacterize non-crystalline materials, local order, recrystallization risk, spray drying feasibility, polymer selection, drug loading, and solid-dispersion stability.
View serviceBuild reproducible crystallization processes that control the chosen solid form, particle attributes, purity, and scale-up behavior.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View serviceA pharmaceutical salt should be selected when ionization provides a meaningful and durable development advantage over the neutral API. Potential advantages include improved dissolution, attainable solution concentration, crystallinity, isolation, purification, handling, stability, or manufacturability. Selection should be based on the complete development profile, because a salt can also introduce hygroscopicity, hydrate or solvate formation, disproportionation, precipitation, counterion burden, or formulation incompatibility.
Good candidates for salt screening contain sufficiently acidic or basic functional groups that can be ionized by a pharmaceutically acceptable counterion. Candidate assessment should consider measured or predicted pKa, intrinsic solubility, pH–solubility behavior, chemical stability, dose, route of administration, and the limitations of the neutral form. A favorable pKa relationship supports proton transfer, but it does not guarantee formation of a crystalline, stable, and developable salt.
Salt-selection programs fail when proton transfer does not produce an isolable crystalline phase or when the resulting salt lacks a durable pharmaceutical advantage. Common causes include weak ionization, poor crystallinity, oiling, excessive hygroscopicity, hydrate or solvate formation, chemical instability, salt disproportionation, difficult processing, and precipitation of the neutral API after dissolution. Programs also fail when candidates are ranked primarily by initial solubility without evaluating solid-state stability, manufacturability, formulation compatibility, and performance in relevant media.
The pKa relationship between an ionizable API and a proposed counterion helps estimate whether proton transfer is thermodynamically favorable. A sufficiently positive ΔpKa generally increases the likelihood of salt formation, but pKa is a solution-phase property and does not determine the final solid state by itself. Crystal packing, solvent, stoichiometry, temperature, hydration, and lattice stability can lead to a salt, cocrystal, mixed protonation state, solvate, or no isolable crystalline product.
Salt screening changes the chemical composition of the material by combining an ionizable API with a counterion and evaluating whether an ionic solid forms. Polymorph screening evaluates different crystalline arrangements of a defined chemical composition. A selected salt is itself a distinct chemical entity for solid-form purposes and may subsequently exhibit its own polymorphs, hydrates, solvates, amorphous phases, and processing-induced transformations.
A pharmaceutical salt can improve dissolution by creating a favorable microenvironmental pH, increasing the concentration gradient at the dissolving surface, and altering wettability, crystal packing, or particle properties. The advantage may be temporary if the salt converts to the neutral API, encounters a common-ion effect, or generates supersaturation followed by precipitation. Salt performance should therefore be evaluated using kinetic, phase-aware studies rather than equilibrium solubility alone.
Salt formation can either improve or reduce long-term stability. A salt may provide a more crystalline, higher-melting, less mobile, or more readily controlled solid than the neutral API. It may also increase hygroscopicity, form hydrates, disproportionate to the free form, or create an acidic or basic microenvironment that accelerates degradation. Stability must therefore be demonstrated experimentally in the drug substance, formulation, packaging configuration, and relevant storage conditions.
Regulators expect a selected pharmaceutical salt to be adequately identified, characterized, manufactured consistently, and controlled according to its effect on drug-substance and drug-product quality and performance. The application should establish salt identity, counterion, stoichiometry, relevant solid forms, manufacturing process, impurities, stability, specifications, and analytical methods. Salt formation does not eliminate the need to understand polymorphism, hydration, solvation, particle properties, dissolution, and process-induced transformation.
Send the material history, current data package, process conditions, development objective, and timeline. Triclinic will route the request to the right solid-form scientist.
